Levonorgestrel intrauterine system in menorrhagia-an effective and acceptable alternative

Barkha A. Bafna; Amit N. Bafna

doi:10.18203/2320-1770.ijrcog20211155

Authors

Barkha A. Bafna Department of Obstetrics and Gynecology, Bafna Hospital, Dhule, Maharashtra, India
Amit N. Bafna Department of Obstetrics and Gynecology, Bafna Hospital, Dhule, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20211155

Keywords:

Levonorgestrel intrauterine system, Menorrhagia, Pictorial blood loss assessment chart

Abstract

Background: To study the efficacy, performance and acceptability of levonorgestrel intrauterine device (LNG-IUS) in treatment of women with menorrhagia.

Methods: This was a descriptive, prospective and observational study conducted over a period of January 2015 to September 2020. Seventy-five (75) women presented with heavy menstrual bleeding having no contraindication for device underwent LNG-IUS insertion after consent. Menstrual pattern, pictorial blood loss assessment chart score (PBAC), rate of acceptability and satisfaction were recorded at 3 months, 6 months, 1, 2 and 3 years after insertion of LNG-IUS.

Results: The most common bleeding pattern at 3 month post-insertion was inter-menstrual spotting followed by infrequent menses, oligomenorrhea and amenorrhea. LNG-IUS caused 45.19% reduction in menstrual blood loss (MBL) at 3 months, 81.48% at 1 year, 91.85% at 2 years and 97% at 3 years. Hemoglobin levels improved from mean baseline 8.9 mg/l to 12.8 mg/l at 3 years. Majority of women were satisfied with this minimally-invasive treatment with continuation rate of 94.66%. No major side-effects were noted.

Conclusions: LNG-IUS is an excellent minimal invasive, highly effective in controlling blood loss and well-tolerated alternative for women with menorrhagia. Its fertility-sparing property makes it an emerging option for young women.

Metrics

Metrics Loading ...

References

Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.

Wright RC. Hysterectomy: past, present, and future. Obstet Gynecol. 1969;33(4):560-3.

Goñi AZ, Lacruz RL, Paricio JJ, Hernández Rivas FJ. The levonorgestrel intrauterine system as an alternative to hysterectomy for the treatment of idiopathic menorrhagia. Gynecol Endocrinol. 2009;25(9):581-6.

Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv. 2002;57(2):120-8.

Taru G, Nupur G, Sangeeta G, Pushpa B, Jyoti J, Sushma K. (2014) Levonorgestrel intrauterine system (LNG IUS) in menorrahgia: a follow-up study. Open J Obstet Gynecol. 2014;4:190-6.

Utman N, Faheem F. Levenorgestrel intra utrine system (LNG IUS) in menorrhagia: a three years followup study. J Postgrad Med Inst. 2011;26(1).

Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625-32.

Chattopdhyay B, Nigam A, Goswami S, Chakravarty PS. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011;15(7):764-8.

Dhamangaonkar PC, Anuradha K, Saxena A. Levonorgestrel intrauterine system (Mirena): an emerging tool for conservative treatment of abnormal uterine bleeding. J Midlife Health. 2015;6:26-30.

Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009;31(4):340-347.

Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-9.

Sushil K, Antony ZK, Mohindra V, Kapur A. Therapeutic use of LNG intrauterine system (Mirena) for menorrhagia due to benign lesions–an alternative to hysterectomy. J Obstet Gynecol India. 2005;55:541-3.

Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97(3):190-4.

Reid PC, Virtanen-Kari S. Randomized comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112(8):1121-5.

Tariq N, Ayub R, Jaffery T, Rahim F, Naseem F, Kamal M. Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception. J Coll Phys Surg Pak. 2011;21(4):210-3.

Vilos GA, Tureanu V, Garcia M, Abu-Rafea B. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy. J Minim Invas Gynecol. 2009;16(4):480-4.

Rodriguez MI, Darney PD. Non-contraceptive applications of the levonorgestrel intrauterine system. Int J Wom Health. 2010;2:63-8.

Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Nat Cancer Inst. 1999;91(13):1131-7.

Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014;121(4):477-86.

Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9:CD012658.